A Phase I PET imaging study to investigate the biodistribution and tumor uptake of BI 765063 and BI 770371 with ezabenlimab (PD-1 inhibitor) in patients with HNSCC, NSCLC or melanoma (NCT05068102)
ECOG PS, Eastern Cooperative Oncology Group performance status; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung carcinoma; RECIST, Response Evaluation Criteria in Solid Tumors; PET, positron emission tomography; Q3W, every 3 weeks; SIRPα, signal-regulatory protein alpha; SUV, standardized uptake values.